Oxytocin intranasal - Turing Pharmaceuticals

Drug Profile

Oxytocin intranasal - Turing Pharmaceuticals

Alternative Names: Syntocinon Nasal Spray; TUR 001

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Developer Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; Foundation for Prader-Willi Research; Icahn School of Medicine at Mount Sinai; Monash University; Montefiore Medical Center; Retrophin; Turing Pharmaceuticals; University Hospital Toulouse; University of California at San Francisco; University of California, San Diego; University of Sao Paulo
  • Class Hormones; Oxytocics
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alcoholism
  • Phase II/III Postnatal depression; Prader-Willi syndrome
  • Phase II Chromosome disorders; Lactation failure
  • Phase 0 Post-traumatic stress disorders
  • Clinical Phase Unknown Schizophrenia
  • Phase Unknown Cocaine abuse; Opioid abuse
  • No development reported Huntington's disease
  • Discontinued Autistic disorder

Most Recent Events

  • 06 Jan 2017 VA Office of Research and Development plans a phase II trial for Opioid abuse and Cocaine abuse in USA (Intranasal) (NCT03016598)
  • 04 Jan 2017 Investigation in Cocaine abuse in USA (Intranasal) before January 2017
  • 04 Jan 2017 Investigation in Opioid abuse in USA (Intranasal) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top